| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10532036 | AFT PHARMS LTD | Combination composition |
Sep, 2025
(1 year, 4 months from now) | |
| US11534407 | AFT PHARMS LTD | Pharmaceutical compostion containing acetominophen and ibuprofen |
Feb, 2039
(14 years from now) | |
| US11197830 | AFT PHARMS LTD | Pharmaceutical composition containing acetaminophen and ibuprofen |
Feb, 2039
(14 years from now) | |
Combogesic is owned by Aft Pharms Ltd.
Combogesic contains Acetaminophen; Ibuprofen.
Combogesic has a total of 3 drug patents out of which 0 drug patents have expired.
Combogesic was authorised for market use on 01 March, 2023.
Combogesic is available in tablet;oral dosage forms.
Combogesic can be used as a method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration.
The generics of Combogesic are possible to be released after 27 February, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 01, 2026 |
Drugs and Companies using ACETAMINOPHEN; IBUPROFEN ingredient
Market Authorisation Date: 01 March, 2023
Treatment: A method of treating mild to moderate acute pain in adults by administering 975-1000 mg of acetaminophen and 292.5-300 mg of ibuprofen in a single administration
Dosage: TABLET;ORAL
COMBOGESIC family patents
